Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
Authors
Serra-Bellver, PatricioVersluis, J. M.
Oberoi, Honey K
Zhou, Cong
Slattery, T. D.
Khan, Y.
Patrinely, J. R.
Pires da Silva, I.
Martínez-Vila, C.
Cook, Natalie
Graham, D. M.
Carlino, M. S.
Menzies, A. M.
Arance, A. M.
Johnson, D. B.
Long, G. V.
Pickering, L.
Larkin, J. M. G.
Blank, C. U.
Lorigan, Paul C
Affiliation
Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United KingdomIssue Date
2022
Metadata
Show full item recordAbstract
Purpose: To assess efficacy and toxicity of combination immunotherapy with ipilimumab plus nivolumab in routine practice in a retrospective multicentre cohort of patients with advanced melanoma. Patients and methods: This retrospective analysis included patients with advanced melanoma treated with ipilimumab and nivolumab between October 2015 and January 2020 at six centres in Australia, Europe and the United States of America. We describe efficacy outcomes (overall survival [OS], progression-free survival [PFS] and objective response rate [ORR]) in treatment-naïve and pre-treated patients, with and without brain metastases, plus treatment-related adverse events (trAEs) in all patients treated. Results: A total of 697 patients were identified; 472 were treatment-naïve of which 138 (29.2%) had brain metastases, and 225 were previously treated of which 102 (45.3%) had brain metastases. At baseline, 32.3% had stage M1c and 34.4% stage M1d disease. Lactate dehydrogenase was high in 280 patients (40.2%). With a median follow-up of 25.9 months, median OS in the 334 treatment-naïve patients without brain metastases was 53.7 months (95% confidence interval [CI] 40.8-NR) and 38.7 months (95% CI 18.6-NR) for the 138 treatment-naïve patients with brain metastases. For the entire cohort the ORR was 48%, for treatment-naïve patients without brain metastases ORR was 56.6% with a median PFS of was 13.7 months (95% CI 9.6-26.5). Median PFS was 7.9 months (95% CI 5.8-10.4) and OS 38 months (95% CI 31-NR) for the entire cohort. Grade 3-4 trAE were reported in 44% of patients, and 4 (0.7%) treatment-related deaths (1 pneumonitis, 2 myocarditis and 1 colitis) were recorded. Conclusion: The outcome and toxicity of combination immunotherapy with ipilimumab and nivolumab in a real-world patient population are similar to those reported in pivotal trials.Citation
Serra-Bellver P, Versluis JM, Oberoi HK, Zhou C, Slattery TD, Khan Y, et al. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. European journal of cancer (Oxford, England : 1990). 2022 Oct 7;176:121-32. PubMed PMID: 36215945. Epub 2022/10/11. eng.Journal
European Journal of CancerDOI
10.1016/j.ejca.2022.09.004PubMed ID
36215945Additional Links
https://dx.doi.org/10.1016/j.ejca.2022.09.004Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2022.09.004